GlassScriptPhysician profile
Anita E Mcdonald
NPI 1336442680
$4,359.68
in general payments reported to CMS, 2019-2025
34 companies · $2,396 in 2025
The $2,396 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $233 · 2023: $274 · 2024: $1,198 · 2025: $2,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Long Term Medical Supply Or Device Loan: $598 · Consulting Fee: $555 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.26 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Consulting Fee | $555.00 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,393.80 | 2024-2025 | |
| Daiichi Sankyo INC. | $354.36 | 2022-2025 | Enhertu, Injectafer |
| Beigene USA, INC. | $285.93 | 2022-2025 | Brukinsa |
| Seagen INC. | $285.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $252.03 | 2021-2025 | Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $201.14 | 2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $153.65 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Beone Medicines USA, INC. | $143.20 | 2025 | Brukinsa, Tevimbra |
| Pfizer INC. | $135.69 | 2024-2025 | |
| Emd Serono, INC. | $95.16 | 2022-2025 | Bavencio |
| Lilly USA, LLC | $94.80 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $91.04 | 2021-2022 | |
| Astellas Pharma US INC | $88.27 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.56 | 2024-2025 | |
| Janssen Biotech, INC. | $66.82 | 2023-2025 | Tecvayli, Darzalex, Erleada |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $56.24 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.48 | 2025 | Iclusig, Ninlaro |
| Pharmaessentia USA Corporation | $53.42 | 2025 | Besremi |
| Abbvie INC. | $51.36 | 2024-2025 | |
| Tersera Therapeutics LLC | $46.53 | 2025 | Zoladex, Quzyttir |
| E.R. Squibb & Sons, L.L.C. | $45.59 | 2024-2025 | Eliquis |
| Genmab U.S., INC. | $45.16 | 2024-2025 | Tivdak |
| Celgene Corporation | $41.00 | 2023-2025 | Reblozyl |
| Array Biopharma INC | $32.92 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Recordati_rare_diseases_inc. | $31.31 | 2025 | Enjaymo |
| Geron Corporation | $24.37 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $24.23 | 2025 | Libtayo |
| Genentech USA, INC. | $22.57 | 2025 | Itovebi |
| Deciphera Pharmaceuticals INC. | $21.08 | 2025 | Tgct, Qinlock |
| Springworks Therapeutics, INC. | $17.58 | 2024 | Ogsiveo |
| Puma Biotechnology, INC. | $16.30 | 2025 | |
| Novocure INC. | $15.84 | 2025 | Optune Lua (Novottf-200t) |
| G1 Therapeutics, INC. | $15.69 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.